Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI